PET/CT with 18F-FDG in the Evaluation of Regional Metastasis of Esophageal Squamous Cell Carcinoma
E. S. Koroleva,
P. E. Tulin,
O. B. Abu-Khaidar,
O. A. Konyakova,
I. S. Grashchenko,
V. V. Solomyany,
A. V. Filimonov https://doi.org/10.37174/2587-7593-2025-8-3-45-51
Abstract
Purpose: To study the diagnostic value of PET/CT with 18F-FDG in evaluation of metastases in lymph nodes of esophageal cancer.
Materials and methods: The retrospective study included 70 patients with squamous cell esophageal cancer. All patients underwent PET/CT with 18F-FDG from 2020 to 2024 in the N.N. Blokhin National Medical Research Center of Oncology. Metastases in the regional lymph nodes were-evaluated by PET/CT with 18F-FDG. Histological verification was performed in all cases.
Results: PET/CT with 18F-FDG demonstrated sensitivity 86 % and specificity 78 % of visualization of metastases in the regional lymph nodes.
Conclusion: PET/CT with 18F-FDG is a promising imaging method in evaluation of cancer extent squamous cell esophageal carcinoma, detecting metastases in unchanged lymph nodes. PET/CT limitations require a comprehensive diagnostic approach.
About the Authors
E. S. Koroleva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Koroleva Elena Sergeevna, 89271152413
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
P. E. Tulin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
O. B. Abu-Khaidar
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
O. A. Konyakova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
I. S. Grashchenko
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
V. V. Solomyany
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
A. V. Filimonov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21841. PMID: 38506106.
2. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. by Kaprin AD, Starinsky VV, Shakhzadova AO. Moscow: P.A. Herzen Moscow State Medical Research Institut. Moscow, 2024. 276 p. (In Russ.).
3. Wang LD, Li X, Song XK, et al. Clinical characteristics of 272 437 patients with different histopathological subtypes of primary esophageal malignant tumors. Zhonghua Nei Ke Za Zhi. 2022;61(9):1023-30. https://doi.org/10.3760/cma.j.cn112138-20210929-00668. PMID: 36008295.
4. Zhang X, Wang Y, Meng L. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharm Sin B. 2022 Mar;12(3):1054-67. https://doi.org/10.1016/j.apsb.2021.09.028. PMID: 35530133.
5. Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024 Jun 3;385:e074962. https://doi.org/10.1136/bmj-2023-074962. PMID: 38830686.
6. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-8. https://doi.org/10.1016/S1470-2045(15)00040-6. PMID: 26254683.
7. Dawsey SM, Wang GQ, Weinstein WM, et al. Squamous dysplasia and early esophageal cancer in the Linxian region of China: distinctive endoscopic lesions. Gastroenterology. 1993 Nov;105(5):1333-40. https://doi.org/10.1016/0016-5085(93)90137-2. PMID: 8224637.
8. Kelly S, Harris KM, Berry E, et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut. 2001 Oct;49(4):534-9. https://doi.org/10.1136/gut.49.4.534. PMID: 11559651.
9. Obermannova R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004. https://doi.org/10.1016/j.annonc.2022.07.003. PMID: 35914638.
10. Van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008 Feb 12;98(3):547-57. https://doi.org/10.1038/sj.bjc.6604200. PMID: 18212745.
11. Goel R, Subramaniam RM, Wachsmann JW. PET/Computed tomography scanning and precision medicine: esophageal cancer. PET Clin. 2017;12(4):373-91. https://doi.org/10.1016/j.cpet.2017.05.001. PMID: 28867110.
12. Deng J, Chu X, Ren Z, et al. Relationship between T stage and survival in distantly metastatic esophageal cancer: A STROBE-compliant study. Medicine (Baltimore). 2020;99(19):e20064. https://doi.org/10.1097/MD.0000000000020064. PMID: 32384472.
13. Shuto K, Kono T, Shiratori T, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in assessing lymph node metastasis of esophageal cancer compared with PET. Esophagus. 2020;17(3):239-49. https://doi.org/10.1007/s10388-019-00704-w. PMID: 31820208.
14. Esophageal and Cardia Cancer. Clinical Recommendations. Ministry of Health of the Russian Federation, Association of Oncologists of Russia, All-Russian Public Organization “Russian Society of Clinical Oncology”, All-Russian Public Organization “Russian Society of Oncopathologists”. Moscow, 2024. (In Russ.). Available at: https://oncology-association.ru/wp-content/uploads/2024/07/kr_rak-pishhevoda-i-kardii_aor_28.06.2024-bez-kommentariev-s-pravkami_final.docx.
15. Lee S, Choi Y, Park G, et al. 18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211024655. https://doi.org/10.1177/15330338211024655. PMID: 34227434.
16. Shi W, Wang W, Wang J, et al. Meta-analysis of 18FDG PETCT for nodal staging in patients with esophageal cancer. Surg Oncol. 2013;22(2):112-16. https://doi.org/10.1016/j.su‑ronc.2013.02.003. PMID: 23478047.
17. Bunting D, Bracey T, Fox B, Berrisford R, Wheatley T, Sanders G. Loco-regional staging accuracy in oesophageal cancer — How good are we in the modern era? Eur J Radiol. 2017;97:71-5. https://doi.org/10.1016/j.ejrad.2017.10.015. PMID: 29153370.
18. Rice TW, Ishwaran H, Ferguson MK, et.al. Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2017 Jan;12(1):36-42. https://doi.org/10.1016/j.jtho.2016.10.016. PMID: 27810391.
19. Liao S, Wei W, Zhang S, et al. Modified method to improve the diagnostic efficiency of 18F-FDG PET/CT in regional lymph node metastasis of esophageal squamous cell carcinoma. Ann Transl Med. 2021 Oct;9(20):1549. https://doi.org/10.21037/atm-21-4926. PMID: 34790755; PMCID: PMC8576671.
20. Yamashita K, Watanabe M, Mine S, et al and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy. World J Surg. 2017 Sep;41(9):2337-2344. https://doi.org/10.1007/s00268-017-4024-5. PMID: 28432391.
21. Liu H, Hu Z, Yang X, et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG uptake in esophageal cancer. Front Oncol. 2022;12:875081. https://doi.org/10.3389/fonc.2022.875081. PMID: 35785188.
22. Liu H, Yang X, You Z, et al. Role of ⁶⁸Ga-FAPI-04 PET/CT in the initial staging of esophageal cancer. Nuklearmedizin. 2023;62(1):38-44. https://doi.org/10.1055/a-1984-8044. PMID: 36746149.
23. Hu J, Zhu D, Yang Y. Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis. Medicine (Baltimore). 2018 Dec;97(50):e13722. https://doi.org/10.1097/MD.0000000000013722. PMID: 30558091.
24. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000 Nov;25(11):882-7. https://doi.org/10.1097/00003072-200011000-00005. PMID: 11079584.
Review
For citations:
Koroleva E.S., Tulin P.E., Abu-Khaidar O., Konyakova O.A., Grashchenko I.S., Solomyany V.V., Filimonov A.V. PET/CT with 18F-FDG in the Evaluation of Regional Metastasis of Esophageal Squamous Cell Carcinoma. Journal of oncology: diagnostic radiology and radiotherapy. 2025;8(3):45-51. (In Russ.) https://doi.org/10.37174/2587-7593-2025-8-3-45-51
Views:
17
Email this article 